Features | Partner Sites | Information | LinkXpress
Sign In
ElsMed
Schiller
Ampronix

New Ultrasound Applications Detects Early Response to Pancreatic Cancer Therapy

By Medimaging International staff writers
Posted on 06 Mar 2013
Image: 3-D Ultrasound Molecular Imaging (USMI) images of nonresponder and responder pancreatic xenografts before (day 0) and after (day 2) treatment. The grayscale image shows a volume of the tumor and surrounding tissue. The green region is the molecular signal (Photo courtesy of the University of North Carolina).
Image: 3-D Ultrasound Molecular Imaging (USMI) images of nonresponder and responder pancreatic xenografts before (day 0) and after (day 2) treatment. The grayscale image shows a volume of the tumor and surrounding tissue. The green region is the molecular signal (Photo courtesy of the University of North Carolina).
In a recent study, investigators utilized dynamic contrast enhanced-perfusion imaging (DCE-PI) and ultrasonic molecular imaging (USMI) to gauge response to therapy for pancreatic cancer.

The research was published in the January 2013 issue journal Technology in Cancer Research and Treatment. Paul Dayton, PhD, University of North Carolina (UNC) Lineberger Comprehensive Cancer Center (Chapel Hill, USA), and senior author of the study, said, “What we found is that using two noninvasive technologies, we can detect response to therapy earlier than by relying on tumor volume changes. Having new noninvasive, inexpensive technologies available to measure response to therapy earlier during the course of treatment would be a significant advance in the ability to tailor a person’s treatment to improve outcomes.”

Dr. Dayton, a UNC associate professor of biomedical engineering, worked with Jen Jen Yeh, M.D, an associate professor of surgery and pharmacology, to assess the imaging technologies on human pancreatic cancer in a preclinical model. Both investigators are members of the Lineberger Comprehensive Cancer Center.

USMI has the ability to depict noninvasively the biologic processes at the cellular and molecular levels. It accomplishes this with the use of targeted contrast agents, which are markers that bind to specific proteins expressed on cancer cells within the body. These contrast agents enable a conventional ultrasound system to identify signals from cancer cells that would otherwise be undetectable.

Ultrasound DCE-PI is a technique used noninvasively to track the blood flow in the microcirculation. Because growing tumors require abnormally increased blood flow, alterations in blood vessel structure or density can provide data regarding tumor malignancy. The researchers employed a drug that suppresses a protein specific to tumors. They then used the imaging applications to gauge the response of two different tumors, one known to respond to the drug therapy, and a second known not to respond. The findings indicated that USMI was able to detect molecular signs of tumor response to therapy after only two days.

A change in blood flow in the tumor was seen to detect response after day 14 using DCE-PI. Over the same period, standard volume measurements were not able to detect therapeutic response, and prior studies suggested that volume measurements do not become indicative of response until approximately 28 days. Therefore, these modalities revealed a substantial improvement in the early identification of tumor response to therapy, using contrast enhanced ultrasound imaging.

The contrast agents for USMI currently in clinical trials in Europe for cancer imaging, however, they are not yet available in the United States.

Related Links:
University of North Carolina Lineberger Comprehensive Cancer Center



Channels

Radiography

view channel
Image: Agfa HealthCare’s DX-D Mobile Retrofit solution will allow hospitals an easy and affordable way to upgrade existing GE Healthcare’s AMX 4 and 4 plus mobile X-ray systems to direct radiography (DR) (Photo courtesy of Agfa Healthcare).

Retrofit Enables Cost-Effective Upgrade of Existing Mobile X-Ray Systems to Direct Radiography

A mobile retrofit system has been designed to be mounted on mobile X-ray systems to create an easy way for hospitals to go digital without having to replace existing mobile X-ray units. A direct radiography... Read more

MRI

view channel
Image: The ischemic penumbra is visible in some patients up to 24 hour after stroke by MRI scanning. Perfusion-weighted imaging can be used to show areas of ischemia and can be compared with the ischemic core, visible by diffusion-weighted imaging (Photo courtesy of sharinginginhealth dot ca, an open access training in healthcare resource).

Diffusion-Weighted MRI Becoming Major Tool to Diagnose Patients with Transient Ischemic Attacks

With the development of brain imaging, including cranial computed tomography (CCT), and particularly diffusion-weighted imaging-magnetic resonance imaging (DWI-MRI), the diagnosis of transient ischemic... Read more

Nuclear medicine

view channel

PET/CT Using FDG-Labeled Leukocytes Detects Infection in Acute Pancreatitis Patients

A study out of India that identifies infection in patients with pancreatic fluid collections may rapidly and effectively rule out active infection in the body. This treatment may help in making nuclear medicine imaging a mainstay in clinical management practices. Acute pancreatitis (AP) is an abrupt inflammation of the pancreas.... Read more

General/Advanced Imaging

view channel

Diagnostic Imaging Tests Ordered by General Practitioners in Australia Nearly Double in 10 Years

A 45% increase in diagnostic imaging tests ordered by Australian general practitioners (GPs) is being fueled by increasing GP visits, an escalating number of problems managed at doctor visits, and a higher probability that GPs order imaging tests for these problems, according to a new study. Based on a long-term national... Read more

Imaging IT

view channel
Image: An X-ray using the ClearRead bone suppression software technology (Photo courtesy of Riverain Technologies).

Bone Suppression Software Used to Optimize Diagnostic Capability of X-Ray Systems

Clinicians are gathering important information from the most routine imaging exam, the chest X-ray, by using advanced software that enhances X-ray images captured by the equipment they already have or... Read more

Industry News

view channel

Acquisition Includes Radiation Simulation Software for Radiotherapy Applications

Varian Medical Systems, Inc. (Palo Alto, CA, USA) has acquired certain assets of Transpire, Inc. (Gig Harbor, WA, USA) including the Acuros dose calculation software, which has been incorporated into Varian’s BrachyVision and Eclipse treatment planning software systems. The acquisition closed at the end of July 2014.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.